Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, food and drug administration
Lilly's weight loss drug shortage deemed over, but hurdles remain
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
Eli Lilly sues 3 vendors selling counterfeit weight-loss drug, including oral versions
The new lawsuits, which name Pivotal Peptides, MangoRx and Genesis Lifestyle Medicine of Nevada, are the first related to copycat tirzepatide filed since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month.
Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs
Mangoceuticals Inc. (MGRX) announced that Eli Lilly has made public allegations and filed a lawsuit against the company, claiming
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit
Mangoceuticals (MGRX) said it strongly refutes claims made in a lawsuit filed by Eli Lilly (LLY) over a compounded version of Lilly’s weight-loss drug tirzepatide. Read more here.
21m
on MSN
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
Alzheimer’s drug donanemab for use in the country's national health service (NHS). The National Institute for Health and Care ...
2h
Lilly's Alzheimer's drug approved in the UK
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...
13h
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
11h
Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report
U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...
13h
on MSN
UK's NHS to block Eli Lilly's Alzheimer's drug on Wednesday, Telegraph reports
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...
BioSpace
20h
Lilly Ups Legal Offensive Against Tirzepatide Copycats as FDA Mulls Shortage Status
Monday’s lawsuits from Eli Lilly are the first to be filed by the pharma since the regulator officially removed tirzepatide ...
Medpage Today on MSN
20h
Why Hospital Gowns Are Ugly; Mass Food Poisoning in Maryland; Eli Lilly Files Suit
In Washington state, four agricultural workers tested presumptively positive for avian influenza after contact with infected ...
7d
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
1h
on MSN
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road that'll pave the way for Eli Lilly (NYSE: LLY) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
New York Stock Exchange
Zepbound
Food and Drug Administration
Alzheimer's disease
Pfizer
Feedback